A Phase 1 interventional study of Dronabinol 10 mg and Dronabinol 30 mg in Drug Abuse, Medication, sponsored by INSYS Therapeutics Inc. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-05-13.
Sponsored by INSYS Therapeutics Inc · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Substance-Related Disorders with a site in Canada — 26 open to participants now, 29 under way, none of them phase 3. Substance-Related Disorders · Canada.
Among the 81 studies in Substance-Related Disorders with a site in Canada, this one is the 48th largest by enrollment of the 71 interventional ones that give a count, is one of 7 that started in 2014, is one of 7 in phase 1, and was the 14th registered.
2,241 studies on the registry are indexed under Substance-Related Disorders; 409 are open to participants now.
Browse Substance-Related Disorders studies →26 of the 81 studies in Substance-Related Disorders with a site in Canada are open now. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–70
St. Joseph's Healthcare Hamilton · Sites in Canada
Ages 18–55
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18–85 · Healthy volunteers
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18–55
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 264 Substance-Related Disorders studies recruiting now, 129 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 89 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 7 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is below the median of 108 across 1,843 interventional studies indexed under Substance-Related Disorders.
Median enrollment 74 across the 71 interventional studies, 520 across the 9 observational. Of the 47 that completed or were terminated, 4 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 81 have an industry lead sponsor. The 10 most frequent:
INSYS Therapeutics Inc is the lead sponsor of 45 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
INSYS Therapeutics Inc has 1 study filed under Substance-Related Disorders — fewer than ten, so there is no comparison to draw.
9 of the studies in Substance-Related Disorders with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04812613Ottawa Hospital Research InstituteTobacco-Concurrent Addictions in At-Risk Youth in Ottawa | 2026-12-31 |
| NCT05704582Ciusss de L'Est de l'Île de MontréalRCT Comparing Avatar Intervention to Supportive Intervention to Reduce Cannabis Use in Patients With Psychotic Disorders | 2027-01 |
| NCT07146633Centre for Addiction and Mental HealthEfficacy of an EMDR App for PTSD and SUD | 2027-01-30 |
| NCT03249428Ottawa Hospital Research InstituteCytisine vs Nicotine Replacement Therapy | 2027-03 |
| NCT06856161Fraser HealthA Novel Blood Test as a Biomarker in Mental Health | 2027-03-15 |
Add all 9 to your calendar (.ics) → With an account.
Among the 81 studies in Substance-Related Disorders with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the abuse potential of dronabinol oral solution in recreational cannabinoid users.
Following a four-day period for screening and qualification, there are five treatment visits with a minimum 8-day washout between treatments. Each participant will receive all treatments in a 5-way crossover design.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each participant receives all treatments (of placebo, dronabinol 10 mg and dronabinol 30 mg) in a 5-way crossover design. At each treatment visit, participants receive a single dose, contained in two syringes of oral solution and three capsules. When dronabinol is in syringes, placebo is in capsules, and when dronabinol is in capsules, placebo is in syringes. When assigned to take placebo only, placebo is in both the syringes and the capsules.
Drug: Dronabinol 10 mg · Drug: Dronabinol 30 mg · Drug: Placebo
Dronabinol at a strength equivalent to 10 mg provided in capsules or as an oral solution in syringes.
Dronabinol at a strength equivalent to 30 mg provided in capsules or as an oral solution in syringes.
Matching placebo provided in capsules or as an oral solution in syringes.
Peak score (Emax) on Drug Liking calculated from a 100-point visual analogue scale (VAS), where 0=strong disliking and 100=strong liking
Time frame: within 24 hours post-dose
Peak score (Emax) for Drug Effects, calculated from scores on a VAS scale of 0-100, where 0=not at all and 100=extremely
Categorical measures = Good drug effects, High, Stoned, Bad effects, Any effects
Time frame: within 24 hours post-dose
Peak score (Emax) for a shortened Addiction Research Center Inventory (ARCI) scale of 0-49, where 49 is the highest possible score
Categorical measures = Euphoria, Dysphoria, Sedation, Marijuana
Time frame: within 24 hours post-dose
Peak score (Emax) for Subjective Drug Value (SDV) in dollars
Time frame: within 24 hours post-dose
Time-averaged Area under the Effect Curve (TA_AUC) for Drug Effects, calculated from scores on a VAS scale of 0-100, where 0=not at all and 100=extremely
Categorical measures = Good drug effects, High, Stoned, Bad effects, Any effects
Time frame: within 24 hours post-dose
Overall Drug Liking (Emax/Emin) calculated from a 100-point visual analogue scale (VAS), where 0=strong disliking and 100=strong liking
Time frame: within 24 hours post-dose
Time-averaged Area under the Effect Curve (TA_AUC) for Drug Liking calculated from a 100-point visual analogue scale (VAS), where 0=strong disliking and 100=strong liking
Time frame: within 24 hours post-dose
Time-averaged Area under the Effect Curve (TA_AUC) for a shortened Addiction Research Center Inventory (ARCI) scale of 0-49, where 49 is the highest possible score
Categorical measures = Euphoria, Dysphoria, Sedation, Marijuana
Time frame: within 24 hours post-dose
Trough Score (Emin) for Drug Liking calculated from a 100-point visual analogue scale (VAS), where 0=strong disliking and 100=strong liking
Time frame: within 24 hours post-dose
Peak score (Emax) for Take Drug Again, calculated from scores on a VAS scale of 0-100, where 0=definitely not and 100=definitely so
Time frame: within 24 hours post-dose
Peak score (Emax) for Alertness/Drowsiness, calculated from scores on a VAS scale of 0-100, where 0=very drowsy and 100=very alert
Time frame: within 24 hours post-dose
Time-averaged Area under the Effect Curve (TA_AUC) for Alertness/Drowsiness, calculated from a 100-point visual analogue scale (VAS), where 0=very drowsy and 100=very alert
Time frame: within 24 hours post-dose
The record gives a start of Feb 2014, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dronabinol